Premixed insulin treatment for type 2 diabetes: analogue or human?
Alan J. Garber,
Robert Ligthelm, Jens S. Christiansen,
Andreas Liebl,
Corresponding Author
Alan J. Garber
Baylor College of Medicine, Faculty Center, Houston, TX, USA
Alan J. Garber, Baylor College of Medicine, Faculty Center, Suite #1000, 1709 Dryden Road, BCM 620, Houston, TX 77030, USAE-mail:agarber@bcm.tmc.edu or llevine@bcm.tmc.eduSearch for more papers by this authorJens S. Christiansen
Department of Endocrinology, Aarhus University Hospital, Denmark
Search for more papers by this authorAndreas Liebl
Center for Diabetes and Metabolism, Fachklinik Bad Heilbrunn, Germany
Search for more papers by this authorAlan J. Garber,
Robert Ligthelm, Jens S. Christiansen,
Andreas Liebl,
Corresponding Author
Alan J. Garber
Baylor College of Medicine, Faculty Center, Houston, TX, USA
Alan J. Garber, Baylor College of Medicine, Faculty Center, Suite #1000, 1709 Dryden Road, BCM 620, Houston, TX 77030, USAE-mail:agarber@bcm.tmc.edu or llevine@bcm.tmc.eduSearch for more papers by this authorJens S. Christiansen
Department of Endocrinology, Aarhus University Hospital, Denmark
Search for more papers by this authorAndreas Liebl
Center for Diabetes and Metabolism, Fachklinik Bad Heilbrunn, Germany
Search for more papers by this authorAbstract
The progressive nature of type 2 diabetes makes insulin initiation a necessary therapeutic step for many patients. Premixed insulin formulations containing both basal and prandial insulin (so called biphasic insulin) are often prescribed because they are superior to long- or intermediate-acting insulin in obtaining good metabolic control. In addition, they are considered as an attractive alternative to classical basal-bolus therapy as fewer daily injections are required. Premixed insulin formulations include conventional (e.g. biphasic human insulin 70/30, or 30/70 in European countries, BHI 30) and newer premixed human analogues (e.g. biphasic insulin aspart 70/30, or 30/70 in Europe, BIAsp 30; insulin lispro mix 75/25–Mix 75/25, or Mix 25/75 in Europe). Like conventional premixed human insulin, premixed insulin analogues contain a fixed proportion of soluble, rapid-acting insulin analogue, with protaminated analogue comprising the remainder. Unlike conventional premixes, analogue premixes have more physiological pharmacokinetic and therapeutically more desirable pharmacodynamic profiles than premixed human insulin. Consequently, postprandial glycaemic control is better with premixed insulin analogues than with premixed human insulin. In nontreat-to-target registration trials, the lowering of haemoglobin A1c with premixed insulin analogues was not inferior to that seen with premixed human insulin. Minor hypoglycaemia was similar for premixed analogue and premixed human insulins, while major hypoglycaemia appears to be rare with either formulation. The occurrence of adverse events, other than hypoglycaemia, was also similar between various premix insulins. The premixed insulin analogues, BIAsp 30 and Mix 75/25, like the fast-acting analogues from which they are derived, also allow flexible injection timing, relative to meal timing, thus improving adherence, compliance and quality of life compared with premixed human insulin. Overall, the evidence suggests that premixed insulin analogues are cost effective and have useful advantages over premixed human insulin for the treatment of type 2 diabetes.
References
- 1 Leahy JL. Pathogenesis of type 2 diabetes mellitus. Arch Med Res 2005; 36: 197–209.
- 2 Bell DS. Importance of postprandial glucose control. South Med J 2001; 94: 804–809.
- 3 Polonsky KS, Given BD, Hirsch LJ et al. Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus. N Engl J Med 1988; 318: 1231–1239.
- 4 Polonsky KS, Sturis J, Bell GI. Non-insulin dependent diabetes mellitus – a genetically programmed failure of the beta cell to compensate for insulin resistance. N Engl J Med 1996; 334: 777–783.
- 5 Coates PA, Ollerton RL, Luzio SD, Ismail I, Owens DR. A glimpse of the ‘natural history’ of established type 2 (non-insulin dependent) diabetes mellitus from the spectrum of metabolic and hormonal responses to a mixed meal at the time of diagnosis. Diabetes Res Clin Pract 1994; 26: 177–187.
- 6 Home PD. Rapid-acting insulin secretagogues: a clinical need? Exp Clin Endocrinol Diabetes 1999; 107(Suppl. 4): S115–119.
- 7 DeWitt DE, Hirsch IB. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review. JAMA 2003; 289: 2254–2264.
- 8 UK Prospective Diabetes Study (UKPDS) Group. United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. Ann Intern Med 1998; 128: 165–175.
- 9 Balkau B, Shipley M, Jarrett RJ et al. High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study. Diabetes Care 1998; 21: 360–367.
- 10 DECODE study group, on behalf of the European Diabetes Epidemiology Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 1999; 354: 617–621.
- 11 DECODE study group, on behalf of the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality. Arch Intern Med 2001; 161: 397–404.
- 12 Stratton IM, Adler AI, Neil HA et al. Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405–412.
- 13 UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837–853.
- 14 Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care 2003; 26: 881–885.
- 15 American Association of Clinical Endocrinologists. Medical guidelines for the management of diabetes mellitus: the AACE system of intensive diabetes self-management–2002 update. Endocr Pract 2002; 8(Suppl. 1): 40–82.
- 16 International Diabetes Federation (European Diabetes Policy Group). A desktop guide to type 2 diabetes mellitus. Diabet Med 1999; 16: 716–730.
- 17 Ceriello A, Bortolotti N, Motz E et al. Meal-induced oxidative stress and low-density lipoprotein oxidation in diabetes: the possible role of hyperglycemia. Metabolism 1999; 48: 1503–1508.
- 18 Ceriello A, Cavarape A, Martinelli L et al. The post-prandial state in type 2 diabetes and endothelial dysfunction: effects of insulin aspart. Diabet Med 2004; 21: 171–175.
- 19 Ceriello A. New insights on oxidative stress and diabetic complications may lead to a ‘causal’ antioxidant therapy. Diabetes Care 2003; 26: 1589–1596.
- 20 Hanefeld M, Fischer S, Julius U et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996; 39: 1577–1583.
- 21 Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999; 281: 20005–20012.
- 22 Gerich JE. Novel insulins: expanding options in diabetes management. Am J Med 2002; 113: 308–316.
- 23 Hirsch IB. Intensifying insulin therapy in patients with type 2 diabetes mellitus. Am J Med 2005; 118(Suppl. 5A): 21S–26S.
- 24 Heinemann L. Overcoming obstacles: new management options. Eur J Endocrinol 2004; 151(Suppl. 2): T23–T27.
- 25 Riddle MC. Making the transition from oral to insulin therapy. Am J Med 2005; 118(Suppl. 5A): 14S–20S.
- 26 Brange J, Owens DR, Kang S, Volund A. Monomeric insulins and their experimental and clinical implications. Diabetes Care 1990; 13: 923–954.
- 27 Barnett AH, Owens DR. Insulin analogs. Lancet 1997; 349: 47–51.
- 28 Brange J. The new era of biotech insulin analogs. Diabetologia 1997; 40(Suppl. 2): S48–S53.
- 29 Kurtzhals P, Schaffer L, Sorensen A et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 2000; 49: 999–1005.
- 30 Gammeltoft S, Hansen BF, Dideriksen L et al. Insulin aspart: a novel rapid-acting human insulin analog. Expert Opin Investig Drugs 1999; 8: 1431–1442.
- 31 Brange J, Volund A. Insulin analogs with improved pharmacokinetic profiles. Adv Drug Deliv Rev 1999; 35: 307–335.
- 32 Bolli GB. Physiological insulin replacement in type 1 diabetes mellitus. Exp Clin Endocrinol Diabetes 2001; 109(Suppl. 2): S317–332.
- 33 Home PD, Barriocanal L, Lindholm A. Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analog, insulin aspart, in healthy volunteers. Eur J Clin Pharmacol 1999; 55: 199–203.
- 34 Mudaliar SR, Lindberg FA, Joyce M et al. Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. Diabetes Care 1999; 22: 1501–1506.
- 35 Gale EA. Insulin lispro: a new quick-acting insulin analog. Expert Opin Investig Drugs 1997; 6: 1247–1256.
- 36 Homko C, Deluzio A, Jimenez C, Kolaczynski JW, Boden G. Comparison of insulin aspart and lispro: pharmacokinetic and metabolic effects. Diabetes Care 2003; 26: 2027–2031.
- 37 Plank J, Wutte A, Brunner G et al. A direct comparison of insulin aspart and insulin lispro in patients with type 1 diabetes. Diabetes Care 2002; 25: 2053–2057.
- 38 Weyer C, Heise T, Heinemann L. Insulin aspart in a 30/70 premixed formulation. Pharmacodynamic properties of a rapid-acting insulin analog in stable mixture. Diabetes Care 1997; 20: 1612–1614.
- 39 Jacobsen LV, Sogaard B, Riis A. Pharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamine-retarded insulin aspart. Eur J Clin Pharmacol 2000; 56: 399–403.
- 40 Hermansen K, Colombo M, Storgaard H et al. Improved postprandial glycemic control with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetes. Diabetes Care 2002; 25: 883–888.
- 41 McSorley P, Bell P, Jacobsen L et al. Twice-daily biphasic insulin aspart 30 vs biphasic human insulin 30: a double-blind crossover study in adults with type 2 diabetes mellitus. Clin Ther 2002; 24: 530–539.
- 42 Heinemann L. Do insulin-treated diabetic patients use an injection-meal-interval in daily life? Diabet Med 1995; 12: 449–450.
- 43 Overmann H, Heinemann L. Injection-meal interval: recommendations of diabetologists and how patients handle it. Diabetes Res Clin Pract 1999; 43: 137–142.
- 44 Heinemann L, Starke AA, Hohmann A, Berger M. Timing between the subcutaneous administration of insulin and consumption of a carbohydrate rich meal. Horm Metab Res Suppl 1992; 26: 137–139.
- 45 Coscelli C, Iacobellis G, Calderini C et al. Importance of premeal injection time in insulin therapy: Humalog Mix 75/25 is convenient for improved post-prandial glycemic control in type 2 diabetic patients with Italian dietary habits. Acta Diabetol 2003; 40: 187–192.
- 46 Kapitza C, Rave K, Ostrowski K, Heise T, Heinemann L. Reduced postprandial glycemic excursion with biphasic insulin Aspart 30 injected immediately before a meal. Diabet Med 2004; 21: 500–501.
- 47 Warren ML, Conway MJ, Klaff LJ, Rosenstock J, Allen E. Postprandial versus preprandial dosing of biphasic insulin aspart in elderly type 2 diabetes patients. Diabetes Res Clin Pract 2004; 66: 23–29.
- 48
Home PD,
Boehm BO,
Bott U,
Behrend C,
Kamp NM,
Lindholm A.
Treatment with premixed insulin aspart 30 in type 1 and type 2 diabetes: a randomized 12-week comparison.
Diabetes Res Clin Pract
2000; 50(Suppl. 1): S37.
10.1016/S0168-8227(00)81585-5 Google Scholar
- 49 Yamada S, Tamada T, Suzuki R, Yajima K, Motohashi Y, Shimada A. Premixed 70/30 insulin aspart suspension improves insulin therapy related QoL in comparison with premixed 70/30 human insulin. Diabetes 2005; 54(Suppl. 1): A119.
- 50 Lammert M, Palmer AJ, Roze S, Minshall ME, Valentine WJ. Decreased rates of major hypoglycaemic events lead to improved long term cost effectiveness of biphasic insulin aspart 30/70 versus biphasic human insulin 30 in type 2 diabetic subjects in Danish, Finnish, German, Norwegian, Spanish, Swedish, and UK Settings. Value Health 2004; 7: 649, DB3.
- 51 Malone JK, Woodworth JR, Arora V et al. Improved postprandial glycemic control with Humalog Mix 75/25/25 after a standard test meal in patients with type 2 diabetes mellitus. Clin Ther 2000; 22: 222–230.
- 52 Mattoo V, Milicevic Z, Malone JK et al. A comparison of insulin lispro Mix 75/25 and human insulin 30/70 in the treatment of type 2 diabetes during Ramadan. Diabetes Res Clin Pract 2003; 59: 137–143.
- 53 Roach P, Yue L, Arora V, the Humalog Mix 75/25 Study Group. Improved postprandial glycemic control during treatment with Humalog Mix 75/25, a novel protamine-based insulin lispro formulation. Diabetes Care 1999; 22: 1258–1261.
- 54 Boehm B, Home P, Behrend C et al. Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in type 1 and type 2 diabetic patients. Diabet Med 2002; 19: 393–399.
- 55 Herz M, Arora V, Campaigne BN, Scholtz HE, Potgieter MA, Mollentze W. Humalog Mix 75/25 improves 24-hour plasma glucose profiles compared with the human insulin mixture 30/70 in patients with type 2 diabetes mellitus. S Afr Med J 2003; 93: 219–223.
- 56 Iwamoto Y. A randomized, multicentre trial of biphasic insulin aspart versus biphasic human insulin in type 2 diabetes. Diabetologia 2003; 46(Suppl. 2): A270.
- 57 Chen J-W, Lauritzen T, Christiansen JJ, Jensen LH, Clausen WHO, Christiansen JS. Pharmacokinetic profiles of biphasic insulin aspart 30/70 and 70/30 in patients with type 1 diabetes: a randomized double-blinded crossover study. Diabet Med 2005; 22: 273–277.
- 58 Jain R, Allen E, Wahl T et al. Efficacy of biphasic insulin aspart 70/30 in patients with T2DM not achieving glycemic targets on OADs with/without basal insulin therapy. Diabetes 2005; 54(Suppl. 1): A69.
- 59 Ushakova O, Sokolovskaya V, Morozova A et al. Biphasic insulin aspart 30 (NovoLog Mix 70/30), a premier analog, is an effective and well tolerated starter insulin in type 2 diabetes. Diabetes 2005; 54(Suppl. 1): A502.
- 60
Ceriello A.
The post-prandial state and cardiovascular disease: relevance to diabetes mellitus.
Diabetes Metab Res Rev
2000; 16: 125–132.
10.1002/(SICI)1520-7560(200003/04)16:2<125::AID-DMRR90>3.0.CO;2-4 CASPubMedWeb of Science®Google Scholar
- 61 Fontbonne A, Eschwege E, Cambien F et al. Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes. Results from the 11-year follow-up of the Paris Prospective Study. Diabetologia 1989; 32: 300–304.
- 62 Schmoelzer I, De Campo A, Pressl H et al. Biphasic insulin aspart compared to biphasic human insulin reduces postprandial hyperlipidemia in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes 2005; 13: 176–181.
- 63 Boehm BO, Vaz JA, Brønstedt L, Home PD. Long-term efficacy and safety of biphasic insulin aspart in patients with type 2 diabetes. Eur J Intern Med 2004; 15: 496–502.
- 64 McNally P, Fitch M, Nelson G. Patients with type 2 diabetes mellitus have lower rates of nocturnal hypoglycemia on biphasic insulin aspart (BIAsp 30) than on biphasic human insulin-30 (BHI30): data from the REACH study. Diabetologia 2004; 47(Suppl. 1): A327.
- 65 Raskin P, Allen E, Hollander P et al. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 2005; 28: 260–265.
- 66 Streja D. Can continuous glucose monitoring provide objective documentation of hypoglycemia unawareness? Endocr Pract 2005; 11: 83–90.
- 67 Lindholm A, Jensen LB, Home PD, Raskin P, Boehm BO, Rastam J. Immune responses to insulin aspart and biphasic insulin aspart in people with type 1 and type 2 diabetes. Diabetes Care 2002; 25: 876–882.
- 68 Home P, Boehm BO, Raastam J, Keiding J. Antibody formation, insulin dose and efficacy in a 4-year comparison of twice daily treatment with biphasic insulin aspart 30 or biphasic human insulin 30. Diabetes 2004; 53(Suppl. 2): A310.
